Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q2 FY24 results · Jul–Sep 2023

Jubilant Pharmova reported revenue from operations of ₹1,680.30 crore (up 5.1% from Q2 FY23) and net profit of ₹62.10 crore (up 1162.2% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY24	Q2 FY23	YoY	Q1 FY24	QoQ
Revenue from operations	1,680.30	1,599.50	+5.1%	1,586.90	+5.9%
Other income	9.90	13.10	−24.4%	8.60	+15.1%
Total income	1,690.20	1,612.60	+4.8%	1,595.50	+5.9%
Profit before share of associates & JVs and tax	89.00	39.06	+127.9%	26.60	+234.6%
Share of profit/(loss) of associates & JVs	9.00	(2.66)		(1.40)
Net profit for the period	62.10	4.92	13x	6.00	+935.0%
Attributable to shareholders of the company	62.50	5.49	11x	6.40	+876.6%
EPS, basic (₹)	3.94	0.34	12x	0.40	+885.0%
Net margin (%)	3.7	0.3		0.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY24	Q2 FY23	YoY	Q1 FY24	QoQ
Revenue from operations	186.30	222.97	−16.4%	217.40	−14.3%
Other income	18.40	106.12	−82.7%	15.90	+15.7%
Total income	204.70	329.09	−37.8%	233.30	−12.3%
Profit before tax	0.20	98.20	−99.8%	2.30	−91.3%
Net profit for the period	(0.40)	91.81	Turned loss	1.90	Turned loss
EPS, basic (₹)	(0.03)	5.77	Turned loss	0.12	Turned loss
Net margin (%)	-0.2	41.2		0.9

Consolidated

Filed with BSE: 30 Oct 2023, 16:38 IST
Board meeting: 27 Oct 2023
Period: 01 Jul 2023 to 30 Sep 2023
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 30 Oct 2023, 16:38 IST
Board meeting: 27 Oct 2023
Period: 01 Jul 2023 to 30 Sep 2023
Review status: Unaudited
Source: XBRL filing on BSE